-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on BioCryst Pharma, Maintains $17 Price Target

Benzinga·08/04/2025 22:11:09
Listen to the news
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $17 price target.